Kitov Pharma (KTOV) Receives Issue Notification for U.S. Patent Covering its anti-CEACAM1 Cancer Drug, CM-24

Kitov Pharma Ltd. (“Kitov”) (NASDAQ: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced receipt from the U.S. Patent and Trademark Office (USPTO) of a Notification of Issuance for a patent application entitled, “Humanized antibodies against CEACAM1.” The patent, which expires in 2035, covers protein and DNA sequences pertaining to humanized antibodies capable of specific binding to human CEACAM1 molecules, including Kitov’s first-in-class monoclonal antibody, CM-24, pharmaceutical compositions comprising these antibodies, as well as methods for their use in treating and diagnosing cancer and other conditions.

“This recognition from the USPTO validates the unique profile of Kitov’s CM-24. The mechanism of action of CM-24 results in an enhanced cytotoxic activity of the immune system cells, inducing a tumor’s death,” commented Isaac Israel, Chief Executive Officer of Kitov. “CEACAM1 expression was found to correlate with poor prognosis in patients with non-small cell lung cancer (NSCLC). We strongly believe that the combination of CM-24 with nivolumab has the potential to result in a significant synergistic benefit in patients with NSCLC tumors expressing CEACAM1. We look forward to the initiation of our phase 1/2 clinical trial with CM-24 in the second half of 2020.”

You May Also Be Interested In

• IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
• Mainz Biomed (MYNZ) Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm
• Immunome Inc. (IMNM) Appoints Sandra M. Swain to its Board